COVID-19 Update #144 1/6/2023

In the 28-day, 26,411 patient, open-label, PANORAMIC trial, adding molnupiravir to usual care did not decrease hospitalization or mortality compared to placebo in vaccinated UK outpatients with mild-to-moderate COVID-19 at risk to progress to severe disease.
 
In a 28-day, 771 patient, Phase III trial (NCT05341609), oral remdesivir analogue, VV116 was non-inferior to nirmatrelvir–ritonavir in the percentage of patients that achieved sustained clinical recovery in Chinese adults with mild-to-moderate COVID—19 with at high risk to progress to severe disease.